Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000524622 | SCV000628040 | pathogenic | Multiple endocrine neoplasia, type 1 | 2017-07-31 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. A different variant (c.1374_1381del, also known in the literature as 1484del8) giving rise to the same protein effect observed here (p.Ser459Glyfs*69) has been reported in an individual affected with MEN1 (PMID: 9215689). This frameshift truncates the functionally conserved nuclear localization signal of the MEN1 protein. Experimental studies have shown that disruption of this region abrogates the ability of MEN1 to bind DNA, regulate target gene expression, and inhibit cell proliferation (PMID: 15331604, 16449969). In addition, a different frameshift variant (p.Arg516Glyfs*43) with a premature termination codon downstream of this frameshift has been reported to be a common cause of multiple endocrine neoplasia type 1 (PMID: 17879353) This variant is not present in population databases (ExAC no frequency). This sequence change results in a premature translational stop signal in the MEN1 gene (p.Ser459Glyfs*69). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 152 amino acids of the MEN1 protein. |